Since Hedin's characterization of trypsin and antitrypsin in 1906,(1) arguably the first
account of a regulatory protein–protein interaction (PPI), contemporary understanding of …

Rapid advancements in genomics have brought a better understanding of molecular
mechanisms for various pathologies and identified a number of highly attractive target …

Protein–protein interactions (PPIs) have emerged as important and challenging targets in
chemical biology and medicinal chemistry. The main difficulty encountered in the discovery …

Protein–protein interactions (PPIs) control the assembly of multi-protein complexes and,
thus, these contacts have enormous potential as drug targets. However, the field has …

The oncoproteins MDM2 and MDMX negatively regulate the activity and stability of the tumor
suppressor protein p53—a cellular process initiated by MDM2 and/or MDMX binding to the …

Protein–protein interactions (PPIs) are key elements of several important biological
processes and have emerged as valuable targets in medicinal chemistry. Importantly …

The overexpression of Hdm2 and HdmX is a common mechanism used by many tumor cells
to inactive the p53 tumor suppressor pathway promoting cell survival. Targeting Hdm2 and …

Background: Over the last two decades, an increasing research effort in academia and
industry has focused on the modulation (both inhibition and stabilization) of protein–protein …

The tremendous challenge of inhibiting therapeutically important protein–protein
interactions has created the opportunity to extend traditional medicinal chemistry to a new …

Cell-penetrating peptides (CPPs) provide promising tools for the cellular delivery of
molecular cargos ranging in size from small molecules and peptides to proteins and …